us as they are, prices are not the real issue. Value is. What really frustrates people are expensive drugs that do not provide a cure. For instance, Opdivo adds an average of 3.2 months of life to lung cancer patients and costs $150,000 per year for treatment. Conversely, other drugs are super- expensiv

s have nearly doubled in the past decade, from an average of $5000 per month to more than $10,000 per month. The price for cancer drugs like Yervoy, Opdivo and Keytruda routinely exceeds $120,000 a year. Some other specialty drugs have even higher prices. Cerezyme for Gaucher disease costs about $300,0

>5%....could be an issue of trial design here. Link to MRK Note About CheckMate -026 CheckMate -026 is a Phase 3, open-label, randomized study of Opdivo as monotherapy versus investigator's choice chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Patients enrolled in the tria

pectations and is likely to broaden over time as data from additional trials support Keytruda's efficacy in a larger patient population. Given that Opdivo is already approved in an all comer sq-NSCLC population and Keytruda has been granted a restricted label, we expect the uptake to be skewed towards